Share Capital (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended						3 Months Ended			6 Months Ended	12 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jan. 31, 2022	Mar. 31, 2021	Jan. 31, 2021	Mar. 31, 2018	Jun. 30, 2022	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2022	Dec. 31, 2018	Jun. 30, 2021
Share Capital [Line Items]
Warrants outstanding to purchase common stock	3,103,864						3,103,864			3,103,864		1,081,081
Warrants exercise description									The Company may not affect the exercise of any pre-funded warrant, and a holder will not be entitled to exercise any portion of any pre-funded warrant that, upon giving effect to such exercise, would cause: (i) the aggregate number of common shares beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the total number of common shares outstanding immediately after giving effect to the exercise; or (ii) the combined voting power of the Company’s securities beneficially owned by such holder, together with its affiliates, to exceed 4.99% of the combined voting power of all of the Company’s securities immediately outstanding after giving effect to the exercise, which percentage may be changed at the holder’s election to a higher or lower percentage not in excess of 19.99% upon at least 61 days’ notice to the Company.
Series 1 Preferred Shares
Share Capital [Line Items]
Conversion of shares		1,016,000									1,852,000
Common Shares [Member]
Share Capital [Line Items]
Conversion of shares		1,016,000									1,852,000
BVF Partners L.P [Member] | Exchange Agreement [Member] | Series 1 Preferred Shares
Share Capital [Line Items]
Shares issued						2,868,000
Preferred shares convertible into common shares						one-for-one
BVF Partners L.P [Member] | Exchange Agreement [Member] | Common Shares [Member]
Share Capital [Line Items]
Shares cancelled						2,868,000
Common Shares [Member]
Share Capital [Line Items]
Shares issued							9,098,362	258,986	5,868,135
Conversion of shares								1,016,000
Common Shares [Member] | Neurocrine Collaboration Agreement [Member]
Share Capital [Line Items]
Shares issued			258,986
Sale proceeds of common shares			$ 8,250
Aggregate purchase price per share			$ 31.855
Jefferies and Stifel [Member] | Underwritten Public Offering [Member]
Share Capital [Line Items]
Shares issued				5,135,135
Shares price				$ 18.50					$ 18.50
Warrants outstanding to purchase common stock				1,081,081					1,081,081
Warrants issued price per pre funded warrant				$ 18.4999					$ 18.4999
Sale proceeds of common shares				$ 107,922
Warrants exercise price per common share				$ 0.0001					$ 0.0001
Number of warrants exercised										0
Jefferies and Stifel [Member] | ATM [Member]
Share Capital [Line Items]
Sale proceeds of common shares					10,693,000
Jefferies and Stifel [Member] | ATM [Member] | Maximum [Member]
Share Capital [Line Items]
Gross proceeds from issuable of common stock										$ 250,000
Jefferies and Stifel [Member] | ATM [Member] | Common Shares [Member]
Share Capital [Line Items]
Shares issued					733,000					0
Jefferies and Stifel [Member] | Over Allotment [Member]
Share Capital [Line Items]
Shares issued				810,810
Neurocrine Biosciences [Member] | License and Collaboration Agreement [Member]
Share Capital [Line Items]
Premium			$ 374
Jefferies, Stifel, J.P. Morgan Securities LLC and SVB Securities LLC [Member] | Underwritten Public Offering [Member]
Share Capital [Line Items]
Shares issued	9,098,362
Shares price	$ 30.50						$ 30.50			$ 30.50
Warrants outstanding to purchase common stock	327,868						327,868			327,868
Warrants issued price per pre funded warrant	$ 30.4999						$ 30.4999			$ 30.4999
Sale proceeds of common shares	$ 269,890
Warrants exercise price per common share	$ 0.0001						$ 0.0001			$ 0.0001
Jefferies, Stifel, J.P. Morgan Securities LLC and SVB Securities LLC [Member] | Over Allotment [Member]
Share Capital [Line Items]
Shares issued	1,229,508